• Endologix appointed Steve Deitsch to its board of directors.
• Deitsch is CEO of Caristo Diagnostics, an AI cardiovascular disease company spun out of University of Oxford.
• He previously served as CFO of OrganOx, where he led its 2025 sale to Terumo for $1.5 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Endologix LLC published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.